Cognitive impairment occurs in a high percentage in all forms of multiple sclerosis, regardless of physical disability. Slowing the speed of information processing is one of the most difficult and the most frequently mentioned, but impairment of memory, attention, executive functions are included also. Long latency event related potentials (ERP) are much more objective means of cognitive functioning evaluation. Different types of immunomodulatory therapies which are used for relapsing- remitting forms of multiple sclerosis may affect the results of ERP. ERP can evaluate subclinical changes and provide important information on the evolution of cognitive changes in patients with MS.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Hoffmann S Tittgemeyer M von Cramon DY.(2007) Cognitive impairment in multiple sclerosis. Curr Opin Neurol 2007; 20(3): 275-80.
2. Amato MP Zipoli V Portaccio E.(2006) Multiple sclerosis-related cognitive changes: a review of crosssectional and longitudinal studies. J Neurol Sci 2006; 245(1-2): 41-6.
3. Barker-Collo SL.(2005) Within session practice effects on the PASAT and clients with multiple sclerosis. Arch Neuropsychol Clin. 2005; 20(2): 145-52.
4. Ivica N Titlic M Pavelin S. (2013) P300 wave changes in patients with multiple sclerosis. Acta Med Inform. 2013; 21(3): 205-7.
5. Piras MR Sognano I Cani ED at all. Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological neuroradiological and neurophysiological findings. J Neurol Neurosurg Psychiatry 2003;74:878-885.
6. Whelan R Lonergan R Kiiski H Nolan H Kinsella K Bramham J O’Brien M Reilly RB Hutchinson M Tubridy N. A high-density ERP study reveals latency amplitude and topographical differences in multiple sclerosis patients versus controls. Clin Neurophysiol 2010;121(9):1420-6.
7. Kiiski H Reilly RB LonerganR at all.(2011) Change in PASAT correlates with in P3 ERP amplitude over a 12-month period in multiple sclerosis patients. Journal of the Neurological Science 2011;305(1):42-52.
8. Sailer M Heinze HJ Tendolkar I Decker U KreyeO v Rolbicki U Münte TF (2001). Influence of cerebral lesion volume and lesion distribution on eventrelated brain potentials in multiple sclerosis. J Neurol 2001;248(12):1049-55.
9. Mathias Sundgren Vadim V Nikulin Liselotte Maurex ÅkeWahlin Fredrik Piehl Tom Brismar. (2015) P300 amplitude and response speed relate to preserved cognitive function in relapsing–remitting multiple sclerosis. Clinical Neurophysiology 2015;126(4):689-697.
10. Filippi M Rocca MA Benedict RHB DeLuca J Geurts JG Rombouts SARB Ron M andComi G. (2010) The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010;75(23): 2121–2128.
11. Mainero C Caramia F Pozzilli C Pisani A Pestalozza I Borriello G et al. (2004) fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 2004;21(3):858-67.
12. Roy S Benedict RH Drake AS Weinstock-Guttman B.(2016) Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. CNS Drug 2016; 30(3): 209-225.
13. Filipovic S Drulovic J Stojisavljevic N Levic Z.(1997) The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. J of Neurological Science 1997;152:147-153.
14. Baykara E Ruf CA Fioravanti C Käthner I Simon N Kleih SC Kübler A Halder.(2016) Effects of training and motivation on auditory P300 brain-computer interface performance. Clin Neurophysiol 2016; 127(1):379-87.